HIV-associated cardiomyopathy: Etiopathogenesis and clinical aspects

Herz

Volumn 30, Issue 6, 2005, Pages 486-492

  Barbaro, Giuseppe ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Acquired immunodeficiency syndrome; Cardiomyopathy; Cytokines; Human immunodeficiency virus; Myocarditis; Tumor necrosis factor

Indexed keywords

ALDOSTERONE ANTAGONIST; ALPHA INTERFERON; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CARVEDILOL; CYTOKINE; DIDANOSINE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXORUBICIN; FOSCARNET SODIUM; IMMUNOGLOBULIN; INDUCIBLE NITRIC OXIDE SYNTHASE; LOOP DIURETIC AGENT; METOPROLOL; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TUMOR NECROSIS FACTOR ALPHA; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; AUTOIMMUNITY; BRAIN DISEASE; CARDIOMYOPATHY; CARDIOTOXICITY; CONGESTIVE CARDIOMYOPATHY; CONGESTIVE HEART FAILURE; COXSACKIE VIRUS B3; CYTOMEGALOVIRUS; DENDRITIC CELL; ESOPHAGITIS; HEART ATRIUM FIBRILLATION; HEART DISEASE; HEART FAILURE; HEART INFARCTION; HEART INJURY; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE CELL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOMODULATION; LUNG DISEASE; MORTALITY; MYOCARDIAL DISEASE; MYOCARDITIS; NONHUMAN; NUTRITIONAL DEFICIENCY; PATHOGENESIS; TOXOPLASMA GONDII; VIRION; VIRUS INFECTION; WASTING SYNDROME;

CARDIOMYOPATHIES; CLINICAL TRIALS; COMORBIDITY; HIV INFECTIONS; HUMANS; INCIDENCE; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES; PREVALENCE; RISK ASSESSMENT; RISK FACTORS;

EID: 25444518453     PISSN: 03409937     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00059-005-2728-z     Document Type: Article

References (35)

1. Barbarini G, Barbaro G. Incidence of the involvement of the cardiovascular system in HIV infection. AIDS 2003;17:Suppl 1:S46-50.
2. Barbaro G, Di Lorenzo G, Grisorio B, et al., and the Gruppo Italiano per lo Studio Cardiologico dei pazienti affetti da AIDS Investigators. Cardiac involvement in the acquired immunodeficiency syndrome: a multicenter clinical-pathological study. AIDS Res Hum Retroviruses 1998;14:1071-7.
3. Barbaro G, Di Lorenzo G, Soldini M, et al., for the Gruppo Italiano per lo Studio Cardiologico dei pazienti affetti da AIDS. Intensity of myocardial expression of inducible nitric oxide synthase influences the clinical course of human immunodeficiency virus-associated cardiomyopathy. Circulation 1999;100:933-9.
4. Barbaro G, Fisher SD, Giancaspro G, et al. HIV-associated cardiovascular complications: a new challenge for emergency physicians. Am J Emerg Med 2001;19:566-74.
5. Bijl M, Dieleman JP, Simoons M, et al. Low prevalence of cardiac abnormalities in an HIV-seropositive population on antiretroviral combination therapy. J Acquir Immune Defic Syndr 2001;27:318-20.
6. Bowles NE, Kearney DL, Ni J, et al. The detection of viral genomes by polymerase chain reaction in the myocardium of pediatric patients with advanced HIV disease. J Am Coll Cardiol 1999;34:857-65.
7. Bristow MR, Mason JW, Billingham ME, et al. Doxorubicin cardiomyopathy: evaluation by phonocardiography endomyocardial biopsy and cardiac catheterization. Ann Intern Med 1978;88:168-75.
8. Brown DL, Sather S, Cheitlin MD. Reversible cardiac dysfunction associated with foscarnet therapy for cytomegalovirus esophagitis in an AIDS patient. Am Heart J 1993;125:1439-41.
9. Cooper ER, Hanson C, Diaz C, et al. Encephalopathy and progression of human immunodeficiency virus disease in a cohort of children with perinatally acquired human immunodeficiency virus infection. J Pediatr 1998;132:808-12.
10. Currie PF, Goldman JH, Caforio AL, et al. Cardiac autoimmunity in HIV related heart muscle disease. Heart 1998;79:599-604.
11. Fiala M, Popik W, Qiao J-H, et al. HIV-1 induces cardiomyopathy by cardiomyocyte invasion and gp120,Tat, and cytokine apoptotic signaling. Cardiovasc Toxicol 2004;4:97-107.
12. Finkel MS, Oddis CV, Jacob TD, et al. Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science 1992;257:387-9.
13. Herskowitz A, Tzyy-Choou W, Willoughby SB, et al. Myocarditis and cardiotropic viral infection associated with severe left ventricular dysfunction in late-stage infection with human immunodeficiency virus. J Am Coll Cardiol 1994;24:1025-32.
14. Hirsch HH, Kaufmann G, Sendi P, et al. Immune reconstitution in HIV-infected patients. Clin Infect Dis 2004;38:1159-66.
15. Klatt EC. Cardiovascular pathology in AIDS. Adv Cardiol 2003;40:23-48.
16. Klatt EC, Nichols L, Noguchi TT. Emerging patterns of heart disease in human immunodeficiency virus infection. Hum Pathol 1994;118:884-90.
17. Lewis W, Grupp IL, Grupp G, et al. Cardiac dysfunction in the HIV-1 transgenic mouse treated with zidovudine. Lab Invest 2000;80:187-97.
18. Lewis W, Simpson JF, Meyer RR. Cardiac mitochondrial DNA polymerase gamma is inhibited competitively and noncompetitively by phosphorylated zidovudine. Circ Res 1994;74:344-8.
19. 2 HIV multicenter study. Circulation 1998;97:1246-56.
20. Lipshultz SE, Easley KA, Orav EJ, et al. Cardiac dysfunction and mortality in HIV-infected children. The Prospective P2C2 HIV Multicenter Study. Circulation 2000;102:1542-8.
21. Lipshultz SE, Easley KA, Orav EJ, et al., for the Pediatric Pulmonary Cardiac Complications of Vertically Transmitted HIV Infection Study Group. Absence of cardiac toxicity of zidovudine in infants. N Engl J Med 2000;343:759-66.
22. Lipshultz SE, Orav EJ, Sanders SP, et al. Immunoglobulins and left ventricular structure and function in pediatrics HIV infection. Circulation 1995;92:2220-5.
23. Liu QN, Reddy S, Sayre JW, et al. Essential role of HIV-1 infected and cyclooxygenase 2 activated macrophages and T cells in HIV type 1 myocarditis. AIDS Res Hum Retroviruses 2001;17:1423-33.
24. Mahrholdt H, Goedecke C, Wagner A, et al. Cardiovascular magnetic resonance assessment of human myocarditis: a comparison to histology and molecular pathology. Circulation 2004;109:1250-8.
25. Matsumori A. Cytokines in myocarditis and cardiomyopathy. Curr Opin Cardiol 1996;11:302-9.
26. Miller TL, Orav EJ, Colan SD, et al. Nutritional status and cardiac mass and function in children infected with the human immunodeficiency virus. Am J Clin Nutr 1997;66:660-4.
27. Nzuobontane D, Blackett KN, Kuaban C. Cardiac involvement in HIV-infected people in Yaounde, Cameroon. Postgrad Med J 2002;78:678-81.
28. Oddò D, Casanova M, Acuna G, et al. Acute Chagas's disease (Trypanosomiasis americana) in acquired immunodeficiency syndrome: report of two cases. Hum Pathol 1992;23:41-4.
29. Ohtsuka T, Hamada M, Hiasa G, et al. Effect of beta-blockers on circulating levels of inflammatory and anti-inflammatory cytokines in patients with dilated cardiomyopathy. J Am Coll Cardiol 2000;37:412-7.
30. Pugliese A, Isnardi D, Saini A, et al. Impact of higly active antiretroviral therapy in HIV-positive patients with cardiac involvement. J Infect 2000;40:282-4.
31. Sartori AM, Lopes MH, Benvenuti LA, et al. Reactivation of Chagas' disease in a human immunodeficiency virus-infected patient leading to severe heart disease with a late positive direct microscopic examination of the blood. Am J Trop Med Hyg 1998;59:784-6.
32. Shannon RP, Simon MA, Mathier MA, et al. Dilated cardiomyopathy associated with simian AIDS in nonhuman primates. Circulation 2000;101:185-93.
33. Sonnenblick EH, Rosin A. Cardiotoxicity of interferon: a review of 44 cases. Chest 1991;99:557-61.
34. Twu C, Liu QN, Popik W, et al. Cardiomyocytes undergo apoptosis in human immunodeficiency virus cardiomyopathy through mitochondrion and death receptor-controlled pathways. Proc Natl Acad Sci USA 2002;99:14386-91.
35. Yokohama T, Vaca L, Rossen RD, et al. Cellular basis for the negative inotropic effect of tumor necrosis factor-alpha in the adult mammalian heart. J Clin Invest 1993;92:2303-12.